Additionally, the analysis revealed that patients with HCC who were resistant to sorafenib treatment exhibited relatively higher expression levels of fatty acid and cholesterol-related genes, including SCD, SREBP1, and HMGCR (Figs. 6D and S7A, B), which was highly correlated with the findings. Here, SREBF1 is linked to hepatocellular carcinoma.